Table 1.

Patient Characteristics, Chimeric Antigen Receptor (CAR)-NK Cell Dose, Treatment Response and Patient Survival

ID	Age	Sex	MGMT	IDH	Prior Treatments	HER2 Score at Screening (0–12)	HER2 Score at Relapse Surgery (0–12)	NK-92/5.28.z Cell Dose	Best Response	PFS (Weeks)	OS (Weeks)	Comments
CB001	49	M	−	WT	S, XRT-TMZ	6	6	1 × 107	SD	7	23
CB002	57	F	−	WT	S, XRT-TMZ	9	2	n.a.	n.a.	n.a.	n.a.	product not released
CB003	60	M	−	WT	S, XRT-TMZ, TTF	2	6	1 × 107	SD	16	18
CB004	44	F	−	WT	S, XRT-TMZ, TTF	2	12	1 × 107	PD	4	22
CB005	46	M	+	WT	S, XRT-TMZ, reS, reXRT, CCNU/TMZ, Nivo	6	6	3 × 107	PD	2	37
CB006	30	M	−	WT	S, XRT-TMZ	8	3	3 × 107	PD	4	40
CB007	57	M	+	WT	S, XRT-TMZ	6	3	3 × 107	PD	3	31
CB008	59	M	+	WT	S, XRT-TMZ	4	8	n.a.	n.a.	n.a.	n.a.	withdrawal of consent
CB009	70	F	+	WT	S, XRT-TMZ	2	6	1 × 108	SD	37	135
CB010	61	M	−	WT	S, XRT-TMZ, reS, TTF	2	9	1 × 108	SD	11	30
CB011	59	M	+	WT	S, XRT-CCNU/TMZ	3	8	1 × 108	SD	37	98

F, female; M, male; MGMT +, MGMT promotor hypermethylation; MGMT -, no MGMT promotor hypermethylation; IDH WT, IDH wild type; CCNU/TMZ, lomustine/temozolomide; reS, relapse surgery; Nivo, Nivolumab; reXRT, relapse radiotherapy; S, surgery; TMZ, temozolomide 5/28; TTF, tumor treating fields; XRT, radiotherapy; XRT-CCNU/TMZ, radiotherapy with CCNU and temozolomide (in accordance with CeTeG); XRT-TMZ, radiotherapy with concomitant and adjuvant temozolomide (in accordance with EORTC 26981); n.a., not applicable; PD, progressive disease; SD, stable disease; PFS, progression-free survival; OS, overall survival. MGMT promotor methylation and IDH status were determined with the Illumina 850k methylation array and data processing via molecularneuropathology.org.